RxDoctor Payments Data

Deepinder Goyal, MD

Gastroenterology · Orlando, FLNPI 1538323399

Payments from drug & device makers

$9,209in general payments, 2019–2025

Across 390 payments — averaging $23.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Ardelyx, Inc.$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • Johnson & Johnson$594
  • Takeda Pharmaceuticals U.S.A., Inc.$435
  • Phathom Pharmaceuticals, Inc.$312
  • plus $3K from 35 others

What the payments were for

  • Consulting fees$1,27614%
  • Food & beverage$7,87886%
  • Education$551%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,209 in reported general payments places this provider in the 70th percentile of 1,388 gastroenterology providers in Florida.

See all gastroenterology providers in Florida

Medicare billing

Part B allowed, 2024
$109,812
Medicare patients
273
Services billed
1,276

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase38$230,006
ZenpepLipase/Protease/Amylase24$97,451
LinzessLinaclotide59$72,166
IbsrelaTenapanor Hcl19$46,833
ClenpiqSod Picosulf/Mag Ox/Citric Ac70$12,063
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates156$9,969
Sucralfate97$7,485
Dexlansoprazole DrDexlansoprazole16$4,103
CholestyramineCholestyramine (With Sugar)39$3,069
Budesonide DrBudesonide11$1,733
Pantoprazole Sodium153$1,640
Famotidine96$1,384
Omeprazole93$1,172
Lactulose41$816
Dicyclomine Hcl22$578

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$2,377$302,17297 claims
Aimmune Therapeutics, Inc.Zenpep$104$97,45124 claims
Ardelyx, Inc.Ibsrela$1,559$46,83319 claims
Ferring Pharmaceuticals Inc.Clenpiq$47$12,06370 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,388 gastroenterology providers in Florida.

Other gastroenterology in Orlando

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →